Allosteric Hemoglobin Modulators for Sickle Cell Oxygenation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders mediated by abnormal hemoglobin, such as sickle cell disease, lack effective therapeutics that can enhance tissue and cellular oxygenation.
Innovation Solution
Development of specific compounds and pharmaceutical compositions that act as allosteric modulators of hemoglobin, specifically targeting hemoglobin S to increase oxygen affinity and treat related disorders like sickle cell anemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no allosteric modulators are administered, then sickle hemoglobin polymerizes and causes sickling, but administering conventional compounds does not sufficiently increase oxygen affinity to effectively treat the disorder
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (Formula I with defined substituents R1-R6, ring systems A-D) that fundamentally alter the oxygen affinity parameter of hemoglobin S. The compounds achieve this through specific chemical interactions at the allosteric site, changing the P50 value and oxygen binding characteristics to prevent sickling while maintaining therapeutic efficacy.
2Shape
If hemoglobin S polymerizes to provide sickle shape, then characteristic sickle cell morphology is achieved, but this polymerization causes rigid cells that block blood vessels
Solution Approach 1:
The patent applies preliminary anti-action by administering allosteric modulator compounds that prevent hemoglobin S polymerization before sickling can occur. The compounds bind to hemoglobin S and stabilize it in a polymerization-resistant conformation, thereby preventing the formation of rigid sickle-shaped cells and their subsequent vasoocclusive effects.
3Use of energy by moving object
If existing compounds are used as allosteric modulators, then some oxygen affinity increase is achieved, but effective treatment of hemoglobin-mediated disorders remains insufficient
Solution Approach 1:
The patent applies composite materials by creating compounds with complex multi-ring structures (aryl and heteroaryl rings A-D with specific substituent patterns) that combine multiple pharmacophoric elements. This composite molecular architecture enables superior allosteric modulation of hemoglobin S compared to simpler compounds, achieving both increased oxygen affinity and reliable therapeutic benefit in treating sickle cell disease and other hemoglobin-mediated disorders.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively increase oxygen affinity of hemoglobin S, addressing oxygen deficiency and providing a therapeutic benefit for treating sickle cell disease and other disorders.
Implementation Method 1
This invention provides compounds and pharmaceutical compositions suitable as allosteric modulators of hemoglobin
Data Source
AI summary
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.